favourable PFS rates at 24 months as compared with detectable MRD: 89.1% vs. 61.9% in
VenG and 93.9% vs. 32.6% in ClbG, respectively. Median PFS was not reached in undetectable
MRD groups. Further landmark analysis of PFS by MRD status showed that undetectable MRD
translated into improved PFS regardless of the clinical response status at EOT.
Conclusion
Fixed-duration treatment with VenG achieves unprecedentedly high and sustainable rates of
undetectable MRD in patients with previously untreated CLL and coexisting conditions.
Findings confirm the prognostic value of MRD assessment at EOT for this chemotherapy-free
treatment regimen. Due to high concordance of undetectable MRD in PB and BM in the
context of VenG, BM assessments may not be required for these patients.
